C6K0
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
C6K0 (C6K0) - Total Assets
Latest total assets as of September 2025: €125.10 Million EUR
Based on the latest financial reports, C6K0 (C6K0) holds total assets worth €125.10 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
C6K0 - Total Assets Trend (2021–2024)
This chart illustrates how C6K0’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
C6K0 - Asset Composition Analysis
Current Asset Composition (December 2024)
C6K0's total assets of €125.10 Million consist of 92.1% current assets and 7.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 89.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €10.50 Million | 7.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how C6K0's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: C6K0's current assets represent 92.1% of total assets in 2024, an increase from 77.1% in 2021.
- Cash Position: Cash and equivalents constituted 89.3% of total assets in 2024, up from 68.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 17.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 7.0% of total assets.
C6K0 Competitors by Total Assets
Key competitors of C6K0 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
C6K0 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - C6K0 generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - C6K0 is currently not profitable relative to its asset base.
C6K0 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.28 | 1.42 | 1.42 |
| Quick Ratio | 14.28 | 1.42 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €105.87 Million | € 25.47 Million | € 25.47 Million |
C6K0 - Advanced Valuation Insights
This section examines the relationship between C6K0's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | 618.0% |
| Total Assets | €150.73 Million |
| Market Capitalization | $146.82 Million USD |
Valuation Analysis
Near Book Valuation: The market values C6K0's assets close to their book value ( 0.97x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: C6K0's assets grew by 618.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for C6K0 (2021–2024)
The table below shows the annual total assets of C6K0 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €150.73 Million | +618.01% |
| 2023-12-31 | €20.99 Million | -37.08% |
| 2022-12-31 | €33.37 Million | -58.40% |
| 2021-12-31 | €80.21 Million | -- |